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Abstract
Objective To examine the efficacy and safety of the therapeutic regimen using oral and intravenous l-arginine for pediatric 
and adult patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS).
Methods In the presence and absence of an ictus of stroke-like episodes within 6 h prior to efficacy assessment, we corre-
spondingly conducted the systematic administration of oral and intravenous l-arginine to 15 and 10 patients with MELAS in 
two, 2-year, prospective, multicenter clinical trials at 10 medical institutions in Japan. Subsequently, patients were followed 
up for 7 years. The primary endpoint in the clinical trial of oral l-arginine was the MELAS scale, while that for intravenous 
l-arginine was the improvement rates of headache and nausea/vomiting at 2 h after completion of the initial intravenous 
administration. The relationships between the ictuses of stroke-like episodes and plasma arginine concentrations were 
examined.
Results Oral l-arginine extended the interictal phase (p = 0.0625) and decreased the incidence and severity of ictuses. Intra-
venous l-arginine improved the rates of four major symptoms—headache, nausea/vomiting, impaired consciousness, and 
visual disturbance. The maximal plasma arginine concentration was 167 μmol/L when an ictus developed. Neither death nor 
bedriddenness occurred during the 2-year clinical trials, and the latter did not develop during the 7-year follow-up despite 
the progressively neurodegenerative and eventually life-threatening nature of MELAS. No treatment-related adverse events 
occurred, and the formulations of l-arginine were well tolerated.
Conclusions The systematic administration of oral and intravenous l-arginine may be therapeutically beneficial and clini-
cally useful for patients with MELAS.
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Introduction
Mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes (MELAS), a clinical phenotype 
of mitochondrial encephalomyopathies [1–3] and first 
reported by Pavlakis et al. [4], is a progressively neurode-
generative and eventually life-threatening mitochondrial 
disorder that causes anatomohistopathological and clinical 
findings (e.g., A3243G point mutation in mtDNA, ragged 
red fibers, and stroke-like episodes). MELAS has the esti-
mated prevalence rate of 10–15 cases per 100,000 persons 
[5], and our 5-year, nationwide, multicenter, prospective 
cohort study in Japan [6] identified MELAS as the most 
common clinicopathologic type of mitochondrial disorders 
and indicated the following facts: the mortality rates from 
sudden death were 17.6% (3/17) and 33.3% (1/3) among 
20 deaths in 58 patients with juvenile-onset MELAS 
(< 18 years) and 38 patients with adult-onset MELAS 
(≥ 18 years), respectively; and juvenile-onset MELAS was 
associated with a significantly higher mortality and more 
rapid disease progression than adult-onset MELAS, with 
a greater risk of renal failure an increasingly recognized 
clinical feature of mitochondrial cytopathies [7]. MELAS 
is distinguishably characterized by the sudden, transient, 
and recurrent development of stroke-resembling symptoms 
(headache, nausea/vomiting, visual disturbance/visual 
field abnormalities, seizures, and impaired consciousness: 
ictus), with the distribution of brain lesions that are incon-
gruent to the usual vascular territories [8]. Furthermore, 
MELAS may manifest clinically in the interictal phase 
(ictus-free phase), “interictal MELAS” and in the acute 
phase (ictus-developing phase) “acute MELAS.”
l-Arginine therapy has been suggested to be beneficial 
for patients with MELAS [6, 9–15]. We had conducted 
a 6-month background survey on the interictal phases of 
candidate patients for our studies. The objective of the 
present clinical research was to examine the efficacy and 
safety of the therapeutic regimen using l-arginine for 
patients with MELAS.
Methods
Study design
The OL-MELAS Research is a 9-year clinical study that 
integrated the pooled data from two, 2-year, phase 3, pro-
spective, multicenter, open-label clinical trials of oral and 
intravenous l-arginine in patients with juvenile- or adult-
onset MELAS; the research was conducted at ten medical 
institutions in Japan in accordance with the Declaration of 
Helsinki and Good Clinical Practice guidelines. The pro-
tocols were approved by the institutional review board at 
each site. Oral l-arginine and intravenous l-arginine were 
purchased commercially (Ajinomoto Pharmaceutical Co., 
Ltd., Tokyo, Japan). The manufacturer was not involved 
in the conduct of the present study at all. All authors were 
involved in data interpretation and manuscript editing, 
vouched for the completeness and accuracy of the data, as 
well as for the compliance of the trials with the protocols, 
and agreed to submit the manuscript for publication. The 
clinical trials were registered at Center for Clinical Trials, 
Japan Medical Association (registry numbers: JMACTR-
IIA00023 and JMACTR-IIA00025).
Research population
Patients were eligible in the clinical trial of oral l-arginine 
if they developed stroke-like episodes in the last 2 years, 
had the A3243G point mutation in mtDNA, had never been 
treated with oral l-arginine, and clinical manifestations of 
stroke-like episodes were evaluable. In the clinical trial of 
intravenous l-arginine, eligible patients were diagnosed with 
MELAS, had the A3243G point mutation in mtDNA, and 
developed an ictus of stroke-like episodes within the previ-
ous 6 h.
Patients, who had been incorporated in the clinical trial of 
intravenous l-arginine from the clinical trial of oral l-argi-
nine or enrolled directly into the former trial, were allowed 
to be bidirectionally and unrestrictedly re-enrolled in the 
clinical trial of oral l-arginine when considered eligible 
(Fig. 1).
Research procedures
Plasma arginine concentrations need to be maintained to 
100 µmol/L at minimum for the preservation of normal 
endothelial function in patients with MELAS [11]. Hence, 
patients received l-arginine 0.3–0.5 g/kg/day orally in three 
divided doses after each meal for 2 years. Patients who 
developed an ictus of stroke-like episodes received l-argi-
nine 0.5 g/kg per dose intravenously, with the additional dos-
ing of intravenous l-arginine 0.5 g/kg per dose at 2 h after 
completion of the initial intravenous administration when 
symptoms did not improve.
Endpoints
In the clinical trial of oral MELAS, the primary endpoint for 
efficacy was the MELAS stroke scale; the secondary end-
points were “the mitochondrial disorder severity scores,” 
“time from oral l-arginine administration to the first ictus 
(time to the first ictus),” and “the migraine severity scores.” 
Six symptoms of stroke-like episodes [headache, nausea/
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vomiting, paresis of the extremities, seizures, impaired con-
sciousness, and visual disturbance (teichopsia and cortical 
blindness)] were scored and integrated in 4-week units. To 
examine the ictus-preventing effect of oral l-arginine, physi-
cians assessed the time to the first ictus by calculating the 
cumulative probability rate according to the Kaplan–Meier 
method. Using the migraine disability assessment score 
questionnaire, physicians calculated the migraine severity 
scores in units of 4 weeks.
In the clinical trial of intravenous l-arginine, the primary 
endpoints for efficacy were the improvement rates of head-
ache and nausea/vomiting at 2 h after completion of the 
initial intravenous administration; the secondary endpoints 
were (1) improvement/no improvement in four major symp-
toms (headache, nausea/vomiting, impaired consciousness, 
and visual disturbance) as assessed based on physician’s 
determinations and changes in the visual analogue scale 
(VAS), (2) changes in each of these four major symptoms, 
and (3) overall assessment based on the physician’s subjec-
tive view (see the protocols). The safety of oral l-arginine 
and intravenous l-arginine was assessed based on adverse 
events (AEs), as well as changes in laboratory values and 
vital signs.
The Japanese mitochondrial disorder rating scale 
(JMDRS) (Table 1) were used to assess MELAS progression 
during the 2-year clinical trials and the subsequent 7-year 
follow-up, and the Newcastle Mitochondrial Disorder Adult 
Scale (NMDAS) [16] during the latter.
Plasma arginine concentrations
In the clinical trial of oral l-arginine, plasma arginine con-
centration were measured at 2 h after ingestion, and the dose 
was adjusted in the dose range of 0.026–0.5 g/kg/day as 
granules to allow the sustainment of plasma arginine con-
centrations of 100 µmol/L at minimum at weeks 4, 8, 12, 24, 
A
B
Clinical trial of oral L-arginine in patients with interictal MELAS*
*: Eligible patients with interictal MELAS were treated with oral L-arginine (0.3-0.5 g/kg/day, tid), and its efficacy 
and safety were assessed at weeks 4, 8, 12, 24, 34, 48, 60, 72, 84, and 96 of treatment.
Clinical trial of intravenous L-arginine in patients with acute MELAS†
†: Patients who developed an ictus of stroke-like episodes within 6 hours prior to the assessment of efficacy and 
safety, whether incorporated via the clinical trial of oral L-arginine or enrolled directly, underwent treatment 
according to the treatment scheme shown in Panel B and were allowed to be unrestrictedly re-enrolled in the 
clinical trial of oral L-arginine when considered eligible.
An ictus of stroke-like
episodes
• Acquisition of consent
• Entry by faxing
1-hr intravenous 
administration of L-arginine 
0.5 g/kg per dose
Assessment 
of efficacy
Unrestricted re-enrollment in the 
clinical trial of oral L-arginine for 
treatment according to the 
scheme shown in Panel A when 
considered eligible
Discontinuation of the clinical trial after assessing
the efficacy and safety of intravenous L-arginine
A
ss
es
sm
en
to
fe
ffi
ca
cy
 
Symptom
deterioration
1-hr additional intravenous 
dosing of L-arginine 0.5 g/kg 
per dose at 2 to 4 hours after 
the completion of the initial 
intravenous administration
2 hrs
2 to 4 hrs
Improvement of 
symptoms
No improvement 
of symptoms
6 hrs
6 hrs 12 hrs
A
ss
es
sm
en
to
fe
ffi
ca
cy
 
A
ss
es
sm
en
to
fe
ffi
ca
cy
 
Fig. 1  Therapeutic regimen using oral and intravenous l-arginine for 
patients with MELAS. a Diagram showing the bidirectionality of the 
therapeutic regimen using oral and intravenous l-arginine for patients 
with interictal or acute MELAS. b Diagram showing the scheme of 
pharmacotherapy with intravenous l-arginine for patients with acute 
MELAS. tid, ter in die; MELAS, mitochondrial myopathy, encepha-
lopathy, lactic acidosis, and stroke-like episodes
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Table 1  JMDRS
Section 1: activities of daily living
 A. Speech
  0: Normal
  1: Mildly affected, no difficulty being understood
  2: Moderately affected, may be asked to repeat
  3: Severely affected, frequently asked to repeat
  4: Unintelligible most of time
 B. Swallowing
  0: Normal
  1: Rare choking
  2: Occasional choking
  3: Requires soft food
  4: Requires nasogastric or gastrostomy tube
 C. Handwriting
  0: Normal
  1: Slightly small or slow
  2: All words small but legible
  3: Severely affected, not all words legible
  4: Majority illegible
 D. Cutting food- handling utensils
  0: Normal
  1: Somewhat slow and clumsy but no help needed
  2: Can cut most foods, some help needed
  3: Food must be cut but can feed self
  4: Needs to be fed
 E. Dressing
  0: Normal
  1: Somewhat slow and clumsy but no help needed
  2: Occasional help with buttons or arms in sleeves
  3: Considerable help required but can do some things alone
  4: Helpless
 F. Hygiene
  0: Normal
  1: Somewhat slow and clumsy but no help needed
  2: Needs help with shower or bath or very slow in hygienic care
  3: Requires assistance for washing, brushing teeth, going to bathroom
  4: Helpless
 G. Falling
  0: None
  1: Rare falling
  2: Less than once per day
  3: Average of once per day
  4: More than once per day
 H. Paroxysmal event (migraine, seizures)
  0: None
  1: < 1 every 1 month
  2: > 1 every 1 month < 1 every week
  3: > 1 every 1 week < 1 every day
  4: > 1 every day/status
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Table 1  (continued)
Section 2: motor
 A. Proximal muscle strength (modified MRC)
  0: Normal
  1: Slight reduction of power (grade 4 MRC)
  2: Moderate impairment, able to overcome gravity (MRC3)
  3: Severe weakness, unable to overcome gravity (MRC2)
  4: Severe weakness, flicker only (MRC1)
  5: No voluntary muscle activity (MRC0)
 B. Upper limb coordination (modified ICARS: International Cooperative Ataxia Rating Scale)
  0: Normal
  1: Mild clumsiness: no significant disability
  2: Moderate clumsiness: poor writing, able to perform ADL
  3: Severe clumsiness: unable to write
  4: Severe clumsiness: unable to feed
 C. Walking
  0: No limitation
  1: Mildly limited (gets tired after 1–2 km)
  2: Moderately limited (difficulties keeping up with friends)
  3: Severe limited (having to stop every 100–400 m to rest)
  4: No walking distance beyond 10 m
 D. Moderate motor activities (e.g., vacuum cleaning, carrying groceries, climbing one flight of stairs, preparing bed)
  0: No limitation
  1: Mildly limited
  2: Moderately limited
  3: Severely limited
  4: Not capable
 E. Vigorous motor activities (e.g., running, climbing several flights of stairs, or participating in other strenuous sports)
  0: No limitation
  1: Mildly limited
  2: Moderately limited
  3: Severely limited
  4: Not capable
Section 3: special sensory
 A. Vision
  0: Normal
  1: Unable to drive or equivalent (i.e., unable to read traffic or shop signs)
  2: Unable to read normal print books
  3: Unable to read standard large print books
  4: Unable to watch TV
  5: No useful vision
 B. Auditory
  0: < 10 dB loss
  1: 10–20 dB loss
  2: 20–40 dB loss
  3: Severe > 40 dB loss but improves with hearing aid
  4: Severe > 40 dB loss and does not improve with hearing aid
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36, 48, 60, 72, 84, and 96. In the clinical trial of intravenous 
l-arginine, plasma arginine concentrations were measured 
before the first intravenous administration at the hospital and 
at 24 h thereafter.
Statistical analysis
For the efficacy analysis, the primary analysis set was the 
full analysis set. Safety was analyzed based on the safety 
analysis set that consisted of patients who received at least 
one dose of the investigational drug. Descriptive statistics 
(e.g., mean, standard deviation, counts, and proportions) 
were summarized as appropriate. The primary endpoint was 
analyzed by one-sample Wilcoxon’s signed-rank test. The 
9-year survival of patients was calculated according to the 
Kaplan–Meier method. The mitochondrial disorder severity 
scores and the migraine severity scores were analyzed by 
one-sample Wilcoxon’s signed-rank test. The improvement 
rates of headache and nausea/vomiting at 2 h after comple-
tion of the initial intravenous administration were calcu-
lated separately and analyzed by Fisher’s exact test. The 
multiplicity issue was adjusted according to the Hochberg 
procedure [17]. One-tailed t-test was conducted to examine 
the between-group difference with respect to the following 
two interictal phases: one between the day of first diagno-
sis and the day of first ictus; and another between 60 days 
prior to the day of first diagnosis and the day of first ictus. 
A value of p < 0.05 (one-tailed) was considered statistically 
significant. All statistical analyses were made with the SAS 
software package version 9.2 (SAS Institute, Cary, NC).
Table 1  (continued)
Section 4: endocrine
 0: Normal
 1: Single endocrine organ involvement
 2: Two endocrine organs involved
 3: Three endocrine organs involved
 For diabetes, add 1 for insulin-treated
Section 5: cardiac
 0: Normal ECG and ECHO
 1: Conduction system disease, mild impaired LV function (EF > 60%) or asymptomatic hypertrophy
 2: ECHO evidence of cardiomyopathy and restricted physical activity (EF < 60%) or cardiac pacemaker, moderate cardiomyopathy 
(EF < 40–60%)
 3: Severe cardiomyopathy
Section 6: renal
 0: Normal
 1: Creatinine clearance < 50–90%
 2: Creatinine clearance 30–50%
 3: Creatinine clearance 10–30%
 4: Creatinine clearance < 10 ml/min or transfusion
Section 7: cognition and impairment
 A. Intellectual impairment
  0: Normal
  1: Mild (consistent forgetfulness with partial recollection of events but no other difficulties)
  2: Moderate memory loss with disorientation and moderate difficulty handing complex problems
  3: Severe memory loss with disorientation as to time and often place, severe impairment with problems
  4: Severe memory loss with orientation only to person, unable to make judgments or solve problems
 B. Motivation and drive
  0: Normal
  1: Lacking in energy, activities not restricted
  2: Lacking in energy, restricts hobbies and interests
  3: Lacking in energy, restricts day-to-day (routine) activities
  4: Unable to carry out any task
JMDRS is modified from the European NeuroMuscular Conference (ENMC) mitochondrial disease rating scale published in Neuromuscular 
Disorders. 2003;13(9):757–764
JMDRS Japanese mitochondrial disease rating scale
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Results
From March 2009 through June 2011, 15 among 96 
patients who had been identified in our cohort study [6] 
were enrolled in the clinical trial of oral l-arginine; three 
discontinued trial treatment due to the increased frequency 
of epileptic seizures, concurrent pneumonia, and unveri-
fied efficacy, respectively. Consequently, 12 completed the 
trial. The efficacy of oral l-arginine was assessed for 13 
patients who were alive but had no data on NMDAS, and 
the safety of the drug for 15 patients. From December 
2008 through March 2011, 10 patients were enrolled in 
the clinical trial of intravenous l-arginine; no treatment 
discontinuation occurred. Hence, ten completed the trial. 
The efficacy and safety of intravenous l-arginine were ana-
lyzed for ten patients each. Five patients were enrolled in 
both clinical trials. Three patients received intravenous 
l-arginine in seven episodes. Two patients with adult-onset 
MELAS one patient each with interictal and acute MELAS 
were lost to follow up due to the transfer of the investi-
gator; they are alive but unevaluable for the JMDRS or 
NMDAS scores. Consequently, 18 and 20 patients were 
analyzed for the efficacy and safety of the therapeutic regi-
men using oral or intravenous l-arginine, respectively.
No patient died or became bedridden at the completion 
of the 2-year clinical trial, and 13 patients were followed 
up until May 31, 2017. At the completion of the 7-year 
follow-up, none of them became bedridden; the numbers 
of patients with interictal and acute MELAS were 11 and 
8, respectively, because 4 deaths had occurred 1 each from 
renal failure and sudden death with respect to interictal 
MELAS, as well as 1 each from sudden death and renal 
and heart failure with respect to acute MELAS. During 
the 7-year follow-up, all patients who had completed the 
2-year clinical trial of intravenous l-arginine received the 
drug when developing an ictus of stroke-like episodes, 
but not all of them received oral l-arginine during the 
interictal phase; on the other hand, all of patients who 
had completed the 2-year clinical trial of oral l-arginine 
continued receiving oral l-arginine during the interictal 
phase and received intravenous l-arginine when develop-
ing an ictus of stroke-like episodes. Patient characteristics 
at baseline, at the completion of the 2-year clinical tri-
als of oral and intravenous l-arginine, and at the comple-
tion of the 7-year follow-up are shown in Tables 2, 3, and 
4, respectively. No ictus developed in five patients with 
interictal MELAS (38.4%), while four (30.8%) experi-
enced three or more ictuses during the clinical trial of oral 
l-arginine. In the subpopulations of patients with interictal 
or acute MELAS, time from diagnosis to the first enroll-
ment/incorporation was longer for juvenile-onset MELAS 
than for adult-onset MELAS (Table 2). Five patients each 
were enrolled in the clinical trials of oral and intravenous 
l-arginine, and four patients were enrolled in the clinical 
trial of intravenous l-arginine only. Four patients, who 
had taken l-arginine other than the study drug prior to the 
onset of the present study, were enrolled in the clinical 
trial of intravenous l-arginine only (Table 3).
In the clinical trial of oral l-arginine, before-after analy-
sis revealed no statistically significant difference in the 
MELAS stroke scale, mitochondrial disease severity scores, 
or migraine severity scores. Namely, l-arginine therapy 
failed to achieve the endpoints. Nevertheless, the p value 
was 0.0549 in changes in the MELAS stroke scale, indi-
cating a tendency of oral l-arginine to improve symptoms. 
The interictal phases, which were assessed with the medians 
of the intervals between the day of first diagnosis and the 
day of first ictus and between 60 days prior to the day of 
first diagnosis and the day of first ictus, were longer after 
administration (p = 0.2500 and p = 0.0625, respectively; one-
tailed test); thus, the interictal phases tended to be extended 
by oral l-arginine. Furthermore, the analysis of the ictus 
incidence ratios (IRRs: the pre- and postadministration inci-
dences) disclosed that the IRRs were below 1 when using 
the ictuses that developed on the day of diagnosis or later 
[IRR 0.84; 95% confidence interval (CI) 0.52–1.36] and on 
60 days prior to the day of diagnosis or later (IRR 0.57; 95% 
CI 0.37–0.86); thus, the IRRs of the ictuses tended to be 
lowered by oral l-arginine. The JMDRS scores in Sections 1 
and 2 at baseline, the end of the 2-year clinical trials, and the 
end of the 7-year follow-up were 7.29 ± 8.77, 10.2 ± 8.48, 
and 24.2 ± 11.7, respectively (Tables 2, 3, 4).
Regarding the efficacy of intravenous l-arginine, fur-
thermore, the improvement rates of headache and nausea/
vomiting at 2 h after completion of the initial intravenous 
administration were 25.0% (2/8) and 50.0% (3/6) (p = 1.0000 
each), respectively. Therefore, the statistical hypothesis that 
“the rate of improvement is greater than 30%” could not 
be tested for these co-primary endpoints. Nevertheless, the 
improvement rates of the co-primary endpoints, headache 
and nausea/vomiting, at 2, 6, 12, and 24 h after completion 
of the initial intravenous administration increased with time: 
for headache, 25.0% (2/8), 12.5% (1/8), 50.0% (4/8), and 
62.5% (5/8), respectively; and for nausea/vomiting, 50.0% 
(3/6), 40.0% (2/5), 80.0% (4/5), and 80.0% (4/5), respec-
tively. Furthermore, the improvement rates of four major 
symptoms increased with time: 100% (12/12) and 83.3% 
(10/12) according to the physician’s determinations and 
changes in the VAS scale. At the completion of the 2-year 
clinical trials, both the bedriddenness and mortality rates 
were 0% (Table 2) despite the progressively neurodegen-
erative and eventually life-threatening nature of MELAS. 
At the completion of 7-year follow-up, the bedriddenness 
rate remained to be 0%; in contrast, the mortality rates of 
patients with juvenile- or adult-onset MELAS were 22.2% 
2868 Journal of Neurology (2018) 265:2861–2874
1 3
and 0.0% in patients with interictal MELAS and were 12.5% 
and 50.0% in patients with acute MELAS (Table 4). The 
9-year survival of patients who were treated with oral and 
intravenous l-arginine is shown in Fig. 2.
Plasma arginine concentrations at baseline and week 96 in 
the clinical trial of oral l-arginine were 65.74 ± 16.74 μmol/L 
and 162.36 ± 45.23 μmol/L, respectively, in 13 patients each 
who had interictal MELAS. Plasma arginine concentra-
tions prior to the onset of intravenous administration and 
at 2 h after completion of the initial intravenous adminis-
tration or discontinuation were 89.81 ± 76.25 μmol/L and 
143.44 ± 122.78 μmol/L, respectively, in 10 patients with 
Table 2  Characteristics of 
pediatric and adult patients 
with interictal or acute MELAS 
at the baseline of the 2-year 
clinical trials of oral and 
intravenous l-arginine
Values are expressed mean ±  SD
MELAS mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, SD standard 
deviation, NA not applicable, JMDRS Japanese mitochondrial disease rating scale
a Five patients each were enrolled in the clinical trials of oral and intravenous l-arginine. N represents the 
full analysis set
b Four patients, who had taken l-arginine other than the study drug prior to the onset of the present study, 
were enrolled in the clinical trial of intravenous l-arginine only
c Score range: 0–81
Characteristics Interictal 
MELAS (N = 13)a
Acute 
MELAS 
(N = 10)a,b
Sex
 Male, no. of patients (%) 7 (53.8) 8 (80.0)
Age, years, no. of patients (%)
 < 18 6 (46.2) 5 (50.0)
 ≥ 18 7 (53.8) 5 (50.0)
 Mean ± SD 20.7 ± 12.5 17.2 ± 5.1
Onset type of MELAS, no. of patients (%)
 Juvenile-onset (< 18 yrs) 8 (61.5) 8 (80.0)
Time from diagnosis to the first enrollment/ incorporation, years
 Juvenile-onset (< 18 years) 1.75 ± 1.67 3.63 ± 3.07
 Adult-onset (≥ 18 years) 0.80 ± 1.10 2.0 ± 1.41
 All onset types 1.38 ± 1.50 3.3 ± 2.83
Number of ictuses that occurred in the last 1 year, no. of patients (%)
 0 5 (38.5) NA
 1 5 (38.5) NA
 2 0 (0.0) NA
 3 1 (7.1) NA
 4 or more 2 (85.8) NA
 Unknown (< 1-year monitoring) 0 (0.0) NA
 All frequency ranges 13 (100.0)
Number of anticonvulsants used previously—no. of patients (%)
 1 8 (61.5) 2 (20)
 2 3 (23.1) 4 (40)
 ≥ 3 2 (15.4) 4 (40)
Duration of treatment with the first anticonvulsant, months
 Mean ± SD 2.29 ± 2.25 3.40 ± 2.67
Plasma arginine concentration, µmol/L
 Mean ±  SD 65.74 ± 16.74 NA
JMDRS—scores in sections 1 and  2c
 0–10: no. of patients (%) 10 (76.9) 5 (50.0)
 11–20: no. of patients (%) 2 (15.4) 3 (30.0)
 21–30: no. of patients (%) 1 (7.7) 2 (20.0)
 ≥ 31: no. of patients (%) 0 (0.0) 0 (0.0)
 All score ranges, mean ±  SD 7.29 ± 8.77 11.1 ± 10.2
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acute MELAS each in the clinical trial of intravenous l-argi-
nine. In a total of 13 patients with interictal MELAS, the 
relationships between plasma arginine concentrations at 
weeks 4, 24, 48, 72, and 96 with the ictuses of stroke-like 
episodes assessed by MRI were examined. Consequently, 
the ictuses developed at a plasma arginine concentration 
Table 3  Characteristics of 
pediatric and adult patients with 
interictal or acute MELAS at 
the end of the 2-year clinical 
trials of oral and intravenous 
l-arginine
Values are expressed mean ± SD
MELAS mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, SD standard 
deviation, NA not applicable, CI confidence interval, MRI magnetic resonance imaging, JMDRS Japanese 
mitochondrial disease rating scale
a Five patients each were enrolled in the clinical trials of oral and intravenous l-arginine, and four patients 
were enrolled in the clinical trial of intravenous l-arginine only. N represents the full analysis set
b Four patients, who had taken l-arginine other than the study drug prior to the onset of the present study, 
were enrolled in the clinical trial of intravenous l-arginine only
c Score range: 0–81
Characteristics Interictal MELAS 
(N = 13)a
Acute 
MELAS 
(N = 10)a,b
Sex
 Male, no. of patients (%) 7 (53.8) 8 (80.0)
Age, years, no. of patients (%)
 < 18 5 (38.5) 5 (50.0)
 ≥ 18 8 (61.5) 5 (50.0)
 Mean ± SD 22.7 ± 12.5 19.2 ± 5.2
Bedriddeness rate, no. of patients (%) 0 (0.0) 0 (0.0)
Time from diagnosis to the first enrollment/incorporation, years
 Juvenile-onset (< 18 years) 1.75 ± 1.67 3.75 ± 2.92
 Adult-onset (≥ 18 years) 0.80 ± 1.10 2.0 ± 1.41
 All onset types 1.38 ± 1.50 3.4 ± 2.72
Plasma arginine concentration, µmol/L
 Prior to the onset of intravenous administration 63.1 ± 11.7
 Mean ± SD NA
 At 24 h after administration or at discontinuation
 Mean ± SD 163.5 ± 44.6 NA
Time from enrollment to the first ictus, days
 Median (95% CI) 397 (151.0) NA
Number of ictuses assessed clinically, no. of patients (%)
 0 5 (38.5) NA
 1 2 (15.4) 7 (70.0)
 2 2 (15.4) 2 (20.0)
 ≥ 3 4 (30.8) 1 (10.0)
Number of ictuses assessed by MRI, no. of patients (%)
 0 8 (61.5) 6 (60.0)
 1 2 (15.4) 3 (30.0)
 2 3 (23.1) 1 (10.0)
 ≥ 3 0 (0.0) 0 (0.0)
Annual increases in the JMDRS  scoresc
 Mean ± SD 1.98 ± 3.19 NA
JMDRS  scoresc in sections 1 and 2
 0–10: no. of patients (%) 9 (69.2) NA
 11–20: no. of patients (%) 2 (15.4) NA
 21–30: no. of patients (%) 2 (15.4) NA
 ≥ 31: no. of patients (%) 0 (0.0) NA
 All score ranges—mean ± SD 10.2 ± 8.48 NA
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Table 4  Characteristics of 
pediatric and adult patients 
with interictal or acute MELAS 
who were followed up for 
7 years after completion of the 
2-year clinical trials of oral and 
intravenous l-arginine
Values are expressed as mean ± SD
MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, SD standard 
deviation, JMDRS Japanese mitochondrial disease rating scale, NMDAS Newcastle mitochondrial disease 
adult scale
a Five patients with MELAS each were enrolled in the clinical trials of oral and intravenous l-arginine. 
Among 13 and 10 patients who completed the respective 2-year trials, two each died during the subsequent 
7-year follow-up. No data on JMDRS and NMDAS were available for 1 “lost-to-follow-up but confirmed to 
be alive” patient each in the trials
b Score range: 0–81
c N represents the full analysis set
d Five patients were enrolled in the clinical trial of intravenous l-arginine only
e The numbers of patients with interictal and acute MELAS were 13 and 10, respectively
f The numbers of patients with interictal and acute MELAS were 11 and 8, respectively, because 4 deaths: 1 
each from renal failure and sudden death with respect to interictal MELAS, as well as 1 each from sudden 
death and renal and heart failure with respect to acute MELAS
g The numbers of patients with interictal and acute MELAS were 10 and 7, respectively, due to the absence 
of a qualified expert to treat MELAS
h Score range: 0–145
Characteristics Interictal MELAS 
(N = 13)a,c
Acute 
MELAS 
(N = 10)a,d
Sex
 Male, no. of patients (%) 7 (53.8) 8 (80.0)
Age, years
 < 18 0 0
 ≥ 18 11 8
 Mean ± SD 30.6 ± 12.7 25.1 ± 5.1
Bedriddeness rate, no. of patients (%) 0 (0.0) 0 (0.0)
Mortality rate by onset  typee, %
 Juvenile-onset (< 18 years) 2/8 (22.2) 1/8 (12.5)
 Adult-onset (≥ 18 years) 0/5 (0.0) 1/2 (50.0)
 All onset types 2/13 (15.4) 2/10 (20.0)
Duration of survival after diagnosis by onset  typef, years
 Juvenile-onset (< 18 years) 10.8 ± 1.7 12.4 ± 3.3
 Adult-onset (≥ 18 years) 9.8 ± 1.1 10.0
 All onset types 10.4 ± 1.5 12.1 ± 3.1
Annual increases in the JMDRS  scoresg,b
 Juvenile (< 18 years) 1.39 ± 0.73 1.38 ± 0.84
 Adult (≥ 18 years) 1.60 ± 0.63 –
 All onset types 1.46 ± 0.78 1.38 ± 0.84
Progression of  MELASg, assessed using the JMDRS  scoresb
 0–10: no. of patients (%) 1 (10) 1 (14.3)
 11–20: no. of patients (%) 4 (40) 2 (25.0)
 21–30: no. of patients (%) 3 (30) 2 (25.0)
 ≥ 31: no. of patients (%) 2 (20) 2 (25.0)
 All score ranges, mean ± SD 24.2 ± 11.7 28.7 ± 14.6
Progression of  MELASg, assessed using the NMDAS  scoresh
 0–20, no. of patients (%) 1 (10) 0 (0)
 21–40, no. of patients (%) 4 (40) 4 (57.1)
 41–60, no. of patients (%) 4 (40) 1 (14.3)
 ≥ 61: no. of patients (%) 1 (10) 2 (28.6)
 All score ranges, mean ± SD 40.3 ± 22.5 48.3 ± 26.3
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of 167 µmol/L or below (Fig. 3). Plasma arginine concen-
trations at 2 h after oral administration were maintained at 
100 μml/L or higher. The median concentrations (range) 
prior to and at 24 h after completion of the initial intravenous 
administration were 51.15 (28.3–224.9) µmol/L and 111.30 
(31.2–520.2) µmol/L, respectively.
Oral l-arginine was well tolerated, and 13 of 15 patients 
completed the 2-year clinical trial. All of 15 patients receiv-
ing oral l-arginine developed stroke-like episodes originat-
ing from MELAS that were adjudicated to be incidental, 
not to be related with oral l-arginine, and mild to moderate 
in severity. Nasopharyngitis (66.7%, 10/15) was the most 
common AE. The following seven episodes of severe AEs 
developed: drug hypersensitivity, increased aspartate ami-
notransferase, increased alanine aminotransferase, increased 
creatinine phosphokinase, metabolic acidosis, arrhyth-
mias, and volvulus. All these patients recovered or became 
alleviated due to the discontinuation or withdrawal of l-argi-
nine. Therefore, oral l-arginine was administrable for a long 
time through careful monitoring of laboratory abnormalities.
On the other hand, 6 (42.9%) among a total of 10 patients 
who received intravenous l-arginine developed AEs. Fever 
was the most common AE in 5 (50.0%) of 10 patients. 
Decreased hematocrit and hemoglobinuria were found in 
three patients each (30.0%), and patients recovered without 
treatment. Six episodes of moderate AEs developed: four 
of fever and one each of epilepsy and bleeding at the injec-
tion site; causality with intravenous l-arginine was denied. 
One episode of severe seizures developed in a patient who 
had been prone to develop seizures since before the trial. 
Laboratory data and vital signs did not show any changes of 
clinical relevance.
Discussion
The present research has integrated the pooled data from 
two small-sized clinical trials of oral and l-arginine in Japa-
nese patients with MELAS that did not adopt the “placebo-
controlled design”, because (1) strong ethical concerns were 
elicited by MELAS a miserable mitochondrial disease that 
could cause irreversible brain damage so severe as leading 
to bedriddenness after one ictus only in patients who would 
have received placebo and (2) impossibility of obtaining 
informed consent from candidate patients to accept a 50% 
probability of receiving placebo despite such a horrible fea-
ture of the disease under the current universal health insur-
ance system in Japan, based on which the institutional review 
board at the participating sites necessarily led to abandon 
the initially designed randomized placebo-controlled trial. 
Furthermore, the trials failed to demonstrate statistically 
significant differences in the primary endpoints. Neverthe-
less, our research provides physicians with the following 
insights of paramount clinical relevance: (1) maintaining 
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plasma arginine concentration ≥ 168 µmol/L may prevent the 
ictuses through the putative pathophysiologic mechanism 
optimal normalization of endothelial dysfunction [11]; (2) 
the bedriddenness rate was 0% at the completion of both the 
2-year clinical trials and the 7-year follow-up, in marked 
contrast to 5.2% in the 5-year cohort study [6]; (3) the mor-
tality rates 0% in five patients with adult-onset, interictal 
MELAS who continued receiving oral l-arginine during the 
interictal phase and were appropriately treated with intra-
venous l-arginine during the acute phase and 50.0% in two 
patients with adult-onset, acute MELAS who were treated 
with intravenous l-arginine but were not treated with oral 
l-arginine during the interictal phase infer that this thera-
peutic regimen is appropriately rationalized to prevent the 
progression and fatal outcome of MELAS; (4) sudden death 
occurred in two patients with juvenile-onset MELAS, one 
each in the clinical trials of oral and intravenous l-arginine, 
implying the eventually life-threatening nature of MELAS; 
(5) MELAS was well controlled in the 2-year clinical tri-
als as indicated by a little change in the JMDRS scores; 
and (6) this therapeutic regimen alone was not sufficient to 
stem disease progression during the 7-year follow-up in real-
world clinical practice, where the clinical control of patients 
became less strict, as evidenced by greater increases in the 
JMDRS scores compared to the scores’ changes found at 
the end of the 2-year clinical trials, i.e., the invariably pro-
gressive nature of MELAS was confirmed and disease pro-
gression might have been furthered by less rigorous clinical 
control. However, our results afford clinical evidence on the 
therapeutic regimen of l-arginine therapy that is enough to 
satisfy the “unmet desire [18]” of pediatricians and neurolo-
gists around the world who are daily dedicated to the treat-
ment of patients with MELAS.
Moreover, the abovementioned insights have the follow-
ing medical implications for the routine care of patients 
with MELAS: (1) these patients can be well controlled and 
disease progression may be retarded when this therapeu-
tic regimen is conducted strictly on an as-needed basis; (2) 
due to the progressively neurodegenerative and eventually 
life-threatening nature of MELAS, the regimen may require 
further therapeutic contrivances (e.g., a medication more 
strictly tailored to individual patients and the regular moni-
toring of plasma arginine concentrations) in an attempt to 
prevent or retard disease progression for years; and (3) clini-
cians who treat patients with MELAS are strongly encour-
aged to implement the regimen as strictly as for clinical 
trials.
l-Arginine is a precursor for nitric oxide (NO) synthesis, 
and its oral or intravenous administration at relatively large 
doses has been shown to enhance the formation of NO in 
individuals with impaired endothelial function [19]. The 
impaired formation or dysfunction of NO in the vascula-
ture is an important pathogenic factor in the development 
of vasculopathies [20]. On the other hand, asymmetrical 
dimethylarginine (ADMA)—an endogenous competi-
tive inhibitor of NO synthase [19, 21] and a risk factor for 
ischemic heart disease [13], atherosclerosis [19, 21], and 
endothelial dysfunction [9–14, 22–28]—may determine an 
individual’s response to l-arginine supplementation [20]; its 
accumulation impairs the formation of NO in vascular dis-
eases [25]. Patients with MELAS invariably show endothe-
lial dysfunction [10–14, 21, 22, 25, 26] that is caused by 
the impairment of endothelium-dependent, NO-mediated 
vasodilatation in which l-arginine plays an important role 
[10–14, 24, 26]. Low plasma arginine concentrations and 
relatively high ADMA concentrations in patients with 
MELAS may predispose the ictus of stroke-like episodes 
[10, 12, 24, 26], and endothelial dysfunction can be reversed 
by exogenous l-arginine [10–12, 26]. Hence, clinicopatho-
logic evidence underpins l-arginine therapy for patients with 
MELAS [10–14, 27–30].
All patients receiving oral l-arginine developed AEs (e.g., 
nasopharyngitis, drug hypersensitivity, and increased lac-
tate dehydrogenase). However, all AEs found during oral or 
intravenous l-arginine were transient and manageable clini-
cally without requiring medications in particular, and any 
severe concerns about the safety of these formulations were 
not elicited at all. These are fully in line with the fact that 
intravenous l-arginine is generally used, without any severe 
reported AEs, the screening for growth hormone insuffi-
ciency around the world.
Little long-term clinical study is available that has exam-
ined the disease severity and progression of mitochondrial 
diseases that involve the most common variant m.3243 
A>G in the mt-rRNALeu. In 2018, a long-term cohort study 
in the UK [31] was published that had recruited 242 adult 
m.3243A>G carriers between 2005 and 2017 to deter-
mine which putative prognostic factors are most associated 
with m.3243A>G-related mitochondrial disease burden 
and progression. Consequently, increasing age as well as 
interactions between age and increasing age-adjusted blood 
mitochondrial DNA heteroplasmy level were significantly 
positively associated with disease progression (p < 0.001), 
although interindividual variation was extremely high. In 
consideration of the chronically progressive and eventual 
fatal clinical course of MELAS, clinicians who treat patients 
with mitochondria diseases are advocated to use patient age 
and age-adjusted blood m.3243A>G mutation load as indi-
cators for disease burden and progression.
The present research has several limitations. First, the 
number of patients with MELAS was small—a fact that 
reduces the statistical impact of the present research. How-
ever, one can never make a simple comparison with clini-
cal trials on other diseases that affect a much greater num-
ber of individuals. Therefore, due regard should be given 
to the fact that MELAS a major clinicopathologic type of 
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mitochondrial diseases is an orphan disease (estimated prev-
alence rate of 10–15 cases per 100,000 persons) that was 
designated to be one of intractable disorders by the Japanese 
government in 2009. We had barely identified among 233 
patients with MELAS in whole Japan 96 patients who could 
complete a 5-year, nationwide, multicenter, prospective 
cohort study [6] the only nationwide epidemiologic study 
on this patient group available in the world that revealed 
the natural course of patients with MELAS (time from 
diagnosis to death: 7.3 ± 5.0 years; mortality rate: 20.8%). 
In the present clinical research, 15 and 10 patients among 
these 96 patients constituted the clinically valuable groups 
of patients who underwent treatment with oral and intrave-
nous l-arginine, respectively. In real-world clinical practice, 
the number of patients with an orphan disease like MELAS 
in long-term clinical research would be inevitably limited 
when considering its epidemiologic profiles. Second, the 
study design was not “placebo-controlled” due to strong 
ethical concerns as described previously. Hence, selection, 
verification, or incorporation bias cannot be ruled out. Third, 
the primary endpoints of the clinical trial of l-arginine could 
not be achieved. We speculate that the extended window for 
intravenous administration from “3 h” in our previous clini-
cal study [9] to “6 h” in the present clinical trial might have 
disadvantageously attenuated the pharmacological effects of 
intravenous l-arginine. All these methodological and statisti-
cal issues may restrict the unobjectionable acceptance of our 
data. Nevertheless, our research is therapeutically unique in 
the following achievements: (a) specification of the plasma 
arginine concentration (trough level: 168 µmol/L) at which 
l-arginine is of potential reference value for preventing an 
ictus that may cause irreversible brain damage, or bedridde-
ness in the worst case—however, its validation by the further 
accumulation of clinical evidence is required; (b) presen-
tation of “0%” in the bedriddenness rate during the strict 
systematic administration of oral and intravenous l-arginine 
in the 2-year clinical trials; and (c) the obvious suppression 
and modest retardation of disease progression at the ends 
of 2-year clinical trials and 7-year follow-up, respectively.
In conclusion, the present research underpins the system-
atic administration of oral and intravenous l-arginine. There-
fore, this regimen may be therapeutically beneficial and 
clinically useful for patients with MELAS. A placebo-con-
trolled study of oral and intravenous l-arginine in patients 
with MELAS will provide clinical evidence to strengthen 
the findings of the present research.
Acknowledgements The authors are grateful to Satoshi Sakima, 
MD, for his valuable suggestions for and linguistical editing of the 
manuscript.
Author contributions YK: study concept and design, literature search, 
clinical data collection, data analysis, data interpretation, writing 
of the manuscript, critical revision of the manuscript for important 
intellectual content, funding acquisition, and study supervision. NP: 
study concept and design, data analysis, interpretation, and critical 
revision of the manuscript for important intellectual content. EI: data 
interpretation and statistical analysis. HN: clinical data collection, data 
analysis, and data interpretation. AI: clinical data collection, data anal-
ysis, and data interpretation. YS: clinical data collection, data analysis, 
and data interpretation. MY: clinical data collection, data analysis, and 
data interpretation. FK: clinical data collection, data analysis, and data 
interpretation. MK: clinical data collection, data analysis, and data 
interpretation. HO: clinical data collection, data analysis, data inter-
pretation. KF: clinical data collection, data analysis, and data interpre-
tation. All authors confirmed the final approval for this version to be 
published and are accountable for all aspect of the research.
Funding This study was funded by the Ministry of Health, Labour 
and Welfare of Japan (H14-Shouni-006) and Center for Clinical Trials, 
the Japan Medical Association Center (CCT-B-1803, CCT-C-2001).
Compliance with ethical standards 
Conflicts of interest The authors declare that they have no conflicts 
of interest.
Ethical standards The research was performed at 10 medical institu-
tions in Japan in accordance with international guidelines, including 
the Declaration of Helsinki, Good Clinical Practice, and Council for 
International Organizations of Medical Sciences, International Ethi-
cal Guidelines (NCT02367014). The study protocol was approved by 
individual institutional review committees.
Informed consent Written informed consent was obtained from all 
subjects or from his or her legal representative prior to enrolment.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. DiMauro S, Schon EA (2003) Mitochondrial respiratory-chain 
diseases. N Engl J Med 348(26):2656–2668
 2. DiMauro S (2013) Mitochondrial encephalomyopathiesï£§fifty 
years on: the Robert Wartenberg lecture. Neurology 
81(3):281–291
 3. Oldfors A, Tulinius M (2003) Mitochondrial encephalomyopa-
thies. J Neuropathol Exp Neurol 62(3):217–227
 4. Pavlakis SG, Phillips PC, DiMauro S et al (1984) Mitochondrial 
myopathy, encephalopathy, lactic acidosis, and strokelike epi-
sodes: a distinctive clinical syndrome. Ann Neurol 16(4):481–488
 5. Chinnery PF, Turnbull DM (2001) Epidemiology and treatment 
of mitochondrial disorders. Am J Med Genet 106(1):94–101
 6. Yatsuga S, Povalko N, Nishioka J, For MELAS Study Group in 
Japan et al (2012) MELAS: a nationwide prospective cohort study 
of 96 patients in Japan. Biochim Biophys Acta 1820(5):619–624
 7. Seidowsky A, Hoffmann M, Glowacki F et  al (2013) Renal 
involvement in MELAS syndrome—a series of 5 cases and review 
of the literature. Clin Nephrol 80(6):456–663
2874 Journal of Neurology (2018) 265:2861–2874
1 3
 8. Iizuka T, Sakai F (2005) Pathogenesis of stroke-like episodes in 
MELAS: analysis of neurovascular cellular mechanisms. Curr 
Neurovasc Res 2(1):29–45
 9. Koga Y, Ishibashi M, Ueki I et al (2002) Effects of l-arginine on 
the acute phase of strokes in three patients with MELAS. Neurol-
ogy 58(5):827–828
 10. Koga Y, Akita Y, Nishioka J et al (2005) l-Arginine improves 
the symptoms of stroke-like episodes in MELAS. Neurology 
64(4):710–712
 11. Koga Y, Akita Y, Junko N et al (2006) Endothelial dysfunction 
in MELAS improved by l-arginine supplementation. Neurology 
66(11):1766–1769
 12. Koga Y, Akita Y, Nishioka J et al (2007) MELAS and l-arginine 
therapy. Mitochondrion 7(1–2):133–139
 13. Koga Y, Povalko N, Nishioka J et al (2010) MELAS and l-argi-
nine therapy: pathophysiology of stroke-like episodes. Ann N Y 
Acad Sci 1201:104–110
 14. Koga Y, Povalko N, Nishioka J et al (2012) Molecular pathol-
ogy of MELAS and l-arginine effects. Biochim Biophys Acta 
1820(5):608–614
 15. DiMauro S, Hirano M. Adam MP et al (1993) Seattle (WA), Uni-
versity of Washington Seattle, GeneReviews® [Internet]. https ://
www.ncbi.nlm.nih.gov/books /NBK12 33/. Accessed 21 Nov 2013
 16. Schaefer AM, Phoenix C, Elson JL et al (2006) Mitochondrial 
disease in adults: a scale to monitor progression and treatment. 
Neurology 66(12):1932–1934
 17. Hochberg Y (1988) A sharper Bonferroni procedure for multiple 
significance testing. Biometrika 75(4):800–802
 18. Koenig MK, Emrick L, Karaa A et al (2016) Recommendations 
for the management of strokelike episodes in patients with mito-
chondrial encephalomyopathy, lactic acidosis, and strokelike epi-
sodes. JAMA Neurol 73(5):591–594
 19. Böger RH (2007) The pharmacodynamics of l-arginine. J Nutr 
137(6 Suppl 2):1650S–1655S
 20. Böger RH, Bode-Böger SM, Frölich JC (1996) The l-arginine-
nitric oxide pathway: role in atherosclerosis and therapeutic impli-
cations. Atherosclerosis 127(1):1–11
 21. Böger RH, Bode-Böger SM, Szuba A et al (1998) Asymmetric 
dimethylarginine (ADMA): a novel risk factor for endothelial 
dysfunction: its role in hypercholesterolemia. Circulation 
98(18):1842–1847
 22. Ito A, Tsao PS, Adimoolam S et al (1999) Novel mechanism for 
endothelial dysfunction dysregulation of dimethylarginine dimeth-
ylaminohydrolase. Circulation 99(24):3092–3095
 23. Ding H, Triggle CR (2005) Endothelial cell dysfunction and the 
vascular complications associated with type 2 diabetes: assess-
ing the health of the endothelium. Vasc Health Risk Manag 
1(1):55–71
 24. Moncada S, Higgs A (1993) The l-arginine-nitric oxide pathway. 
N Engl J Med 329(2):2002–2012
 25. Piatti PM, Fragasso G, Monti LD et al (2003) Acute intravenous 
l-arginine infusion decreases endothelin-1 levels and improves 
endothelial function in patients with angina pectoris and normal 
coronary arteriograms. Circulation 107(3):429–436
 26. Hambrecht R, Hilbrich L, Erbs S et  al (2000) Correction of 
endothelial dysfunction in chronic heart failure: additional effects 
of exercise training and oral l-arginine supplementation. J Am 
Coll Cardiol 35(3):706–713
 27. Betts J, Jaros E, Perry RH et al (2006) Molecular neuropathol-
ogy of MELAS: level of heteroplasmy in individual neurons and 
evidence of extensive vascular involvement. Neuropathol Appl 
Neurobiol 32(4):359–373
 28. De Paepe B, Smet J, Lammens M et al (2009) Immunohistochemi-
cal analysis of the oxidative phosphorylation complexes in skeletal 
muscle from patients with mitochondrial DNA encoded tRNA 
gene defects. J Clin Pathol 62(2):172–176
 29. Rodan LH, Wells GD, Banks L et al (2015) l-Arginine affects 
aerobic capacity and muscle metabolism in MELAS (mitochon-
drial encephalomyopathy, lactic acidosis and stroke-like episodes) 
syndrome. PLoS One 10(5):e0127066
 30. Kitamura M, Yatsuga S, Abe T et al (2016) l-Arginine interven-
tion at hyper-acute phase protects the prolonged MRI abnormality 
in MELAS. J Neurol 263(8):1666–1668
 31. Grady JP, Pickett SJ, Ng YS et al (2018) mtDNA heteroplasmy 
level and copy number indicate disease burden in m.3243A>G 
mitochondrial disease. EMBO Mol Med 10(6):e8262
